
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR04-484
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Prosoft Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
Details : ATR04-484 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Exanthema.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : ATR04-484
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Prosoft Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
Details : ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain. It is being evaluated for the treatment of EGFRi-associated skin rash.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 28, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Receives FDA IND Clearance to Treat Skin Rash from EGFR Inhibitors
Details : ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain. It is being evaluated for the treatment of EGFRi-associated skin rash.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Recombinant Staphylococcus Epidermidis
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azitra Screens First Patient for Phase 1b Trial of ATR-12 for Netherton Syndrome
Details : ATR12-351 (ATR-12), a novel strain of S. epidermidis that has been genetically modified to express full-length protein LEKTI, being evaluated for the treatment of Netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Azitra, Inc. Announces Closing of Public Offering
Details : Net proceeds will fund ATR12-351 (ATR-12), a modified S. epidermidis strain expressing an active LEKTI fragment, evaluated for Netherton syndrome treatment.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
February 16, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering
Azitra, Inc. Announces Pricing of Public Offering
Details : The company intends to use the net proceeds for clinical trials and product development of ATR12-351 (ATR-12) for the treatment of Netherton Syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $5.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR12-351
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Details : ATR12-351 is a Microorganism drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Netherton Syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : ATR12-351
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
Azitra, Inc. Announces Closing of Initial Public Offering
Details : The company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : ATR-12
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Strain of Staphylococcus Epidermidis
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
Azitra, Inc. Announces Pricing of Initial Public Offering
Details : The Company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Strain of Staphylococcus Epidermidis
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Thinkequity
Deal Size : $7.5 million
Deal Type : Public Offering
